GenVec, Inc. (NASDAQ: GNVC) is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Each of our gene-based therapeutic product candidates uses a common patent-protected technology platform to deliver genes that produce medically beneficial proteins directly at the site of disease.

TNFerade™ represents a novel approach to treating cancer in combination with radiation and/or chemotherapy by introducing tumor necrosis factor-alpha (TNF-alpha), a potent anti-cancer protein, directly into tumors.  Pancreatic cancer is the lead indication for TNFerade™.  We are conducting a pivotal 330-patient Phase III clinical trial (the PACT study) designed to assess the safety and clinical benefit of using TNFerade™ in combination with standard of care treatment in patients with locally advanced pancreatic cancer.  In addition to the Phase III PACT study, TNFerade has been and is currently being evaluated for its potential use in other indications such as head and neck cancer, esophageal cancer, and rectal cancer.  

Hearing and Balance Atonal Therapy is a product concept to restore hearing or balance function through the regeneration of critical cells of the inner ear. Hearing and Balance require specialized cells of the inner ear called sensory hair cells. During embryonic development a gene termed atonal (ATOH) induces the generation of these cells.  GenVec has shown preclinically that the production of the ATOH protein results in the formation of new inner ear sensory hair cells, and the restoration of hearing and balance function. TherAtoh is an adenovector product delivering the human atonal gene (Hath1) to trigger the production of therapeutic proteins by cells in the inner ear. 

We also are using GenVec's proprietary adenovector technology to develop vaccines for infectious diseases.

• Foot-and-mouth disease antiviral and vaccine program in collaboration with the United States Department of Agriculture/Agricultural Research Services (USDA-ARS) Worldwide HIV vaccine in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID)
• Malaria vaccine in collaboration with U.S. Navy and PATH's Malaria Vaccine Initiative
• RSV vaccine under an SBIR grant from the NIH 
• HSV-2 under an SBIR grant from NIAID